Avalo Therapeutics Inc. AVTX
$14.33
โฒ +7.97% 24H
About
Avalo Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing IL-1ฮฒ-based treatments for immune-mediated inflammatory diseases with significant unmet needs. The company targets the IL-1ฮฒ pathway, a central driver of inflammation, through its lead asset, abdakibart (AVTX-009), a humanized monโฆ
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees33
TickerAVTX
Statistics
Market Cap$353.1M
Revenue (TTM)$59000
Net Income-$78.3M
Net Margin-132642.4%
EPS$-5.84
P/E2.30
P/S12179.18
P/B4.93
EV/EBITDA-8.07
ROE-88.8%
Dividend Yieldโ
Price$14.33
Data: Twelve Data ยท Revenue = mcap / P/S